(Q38245038)

English

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

scientific article published on 27 August 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Takashi Seto

1

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Terufumi Kato

2

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Makoto Nishio

3

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Koichi Goto

4

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Shinji Atagi

5

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Yukio Hosomi

6

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Noboru Yamamoto

7

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Toyoaki Hida

8

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Makoto Maemondo

9

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Kazuhiko Nakagawa

10

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Seisuke Nagase

11

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Isamu Okamoto

12

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Takeharu Yamanaka

13

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Kosei Tajima

14

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Ryosuke Harada

15

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Masahiro Fukuoka

16

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Nobuyuki Yamamoto

17

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

publication date

27 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

1236-1244

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70381-X

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38245038&oldid=1749067449"